Drug News: October 2010Dexilant: new PPI, lansoprazole enantiomer; Prolia: twice-yearly SC injection for osteoporosis; Thalidomide approved for multiple myeloma. Actemra: anaphylaxis riskHoffmann-La Roche and Health Canada warn about potential risk of fatal anaphylaxis with Actemra (tocilizumab). CMA to consider moving annual meeting from August Thalidomide returns – with a catch Med school admission landscape changing across Canada Requirements being retooled to modernize process and diversify student population How to stop worrying and love artificial sweeteners Many believe that because they are unnatural they must be unsafe, yet research shows they are safe—especially at real-world levels Departing federal watchdog pulls no punches in speech This fall is the swan song tour for Canada’s Auditor-General. Sheila Fraser finishes her 10-year mandate as the federal government’s chief watchdog next spring. Letter: Questioning the role of DPP-4 inhibitors A reader comments on the role of DPP-4 inhibitors in the management of type 2 diabetes. Drug News: Finacea, FluMist, Intanza Finacea: new topical treatment for rosacea; FluMist: first intranasal flu vaccine; Intanza: first intradermal flu vaccine. Celiac disease: the stealthy robber of health There are many myths and misconceptions surrounding celiac disease. First Previous 234 235 236 237 238 Next Last
